EVREUX, France & MONTREAL—In mid-October, CiToxLAB, a contract research organization (CRO), announced the purchase of a new facility in the Laval area of Montreal to meet the growing demand for bioanalysis and biomarkers services in support of preclinical and clinical programs, offering shorter lead times for development programs.

 

The newly acquired Canadian facility is a turn-key, purpose-built laboratory described as “ultra modern” by CiToxLAB, and it is dedicated to small and large molecule bioanalysis by LC-MS/MS and ligand binding assays, flow cytometry, biomarkers, biodistribution by qPCR and immunology—that last category includes anti-drug antibody, neutralizing antibody, immunophenotyping and ELISPOT offerings. This expansion is an integral part of the strategic plan for CiToxLAB’s growth in global laboratory services.

 

“This expansion is the result of successful partnerships with our clients. It reinforces CiToxLAB’s commitment to enhancing the way we serve our customers. The relocation of some of our laboratory operations to this new building will free up areas in the main building, allowing us to increase our animal room capacity, resulting in shorter lead times for our clients,” said Jean-François Le Bigot, chairman and CEO of CiToxLAB Group. “The availability of this building, next door to our site in Laval, was an unexpected but excellent opportunity. I am very satisfied that our fast decision-making led CiToxLAB to acquiring this building in this ever-growing suburb of Montreal, where competition for this type of real estate is very high.”